Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer (mCRC): A preplanned analysis of the phase III AXEPT trial

被引：0

作者：

Xu, R. ^{[1
]}

Muro, K. ^{[2
]}

Kim, T. W. ^{[3
]}

Park, Y. S. ^{[4
]}

Wang, W. ^{[5
]}

Han, S-W. ^{[6
]}

Kotaka, M. ^{[7
]}

Deng, Y-H. ^{[8
]}

Ahn, J. B. ^{[9
]}

Nakamura, M. ^{[10
]}

Ba, Y. ^{[11
]}

Cho, S-H. ^{[12
]}

Kato, T. ^{[13
]}

Zhang, T. ^{[14
]}

Lee, K-W. ^{[15
]}

Matsuoka, H. ^{[16
]}

Fang, W-J. ^{[17
]}

Morita, S. ^{[18
]}

Iwasa, S. ^{[19
]}

Junichi, S. ^{[20
]}

机构：

[1] Sun Yat Sen Univ, Dept Med Oncol, Ctr Canc, Guangzhou, Guangdong, Peoples R China

[2] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan

[3] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea

[4] Samsung Med Ctr, Dept Med, Seoul, South Korea

[5] First Peoples Hosp Foshan, Dept Gastrointestinal Oncol, Foshan, Peoples R China

[6] Seoul Natl Univ Hosp, Internal Med, Seoul, South Korea

[7] Sano Hosp, Gastrointestinal Canc Ctr, Surg, Kobe, Hyogo, Japan

[8] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Med Oncol, Guangzhou, Guangdong, Peoples R China

[9] Yonsei Univ, Severance Hosp, Dept Internal Med, Seoul, South Korea

[10] Aizawa Hosp, Aizawa Comprehens Canc Ctr, Matsumoto, Nagano, Japan

[11] Tianjin Med Univ, Canc Inst & Hosp, Dept Digest Oncol, Tianjin, Peoples R China

[12] Chonnam Natl Univ Hosp, Hematol Oncol, Gwanju, South Korea

[13] Natl Hosp Org Osaka Natl Hosp, Colorectal Surg, Osaka, Japan

[14] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Abdominal Oncol, Wuhan, Hubei, Peoples R China

[15] Seoul Natl Univ, Bundang Hosp, Coll Med, Internal Med, Seongnam, South Korea

[16] Fujita Hlth Univ Hosp, Surg, Toyoake, Aichi, Japan

[17] Zhejiang Univ, Affiliated Hosp 1, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China

[18] Kyoto Univ, Med Stat & Bioinformat, Kyoto, Japan

[19] Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan

[20] Tokai Cent Hosp, Kakamigahara, Japan

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

88O

引用

页数：2

共 50 条

[21] Relationship between UGT1A1*6/*28 gene polymorphisms and the efficacy and toxicity of irinotecan-based chemotherapy
Bai, Yu
Wu, Ai-wei
Ma, Xu
Liu, Ying
Zhang, Yan-hua
ONCOTARGETS AND THERAPY, 2017, 10 : 3071 - 3081
[22] Association of UGT1A1*6 polymorphism with irinotecan-based chemotherapy reaction in colorectal cancer patients: a systematic review and a meta-analysis
Zhu, Xiaoyun
Ma, Ruchao
Ma, Xin
Yang, Gang
BIOSCIENCE REPORTS, 2020, 40
[23] UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study
Kweekel, D. M.
Gelderblom, H.
Van der Straaten, T.
Antonini, N. F.
Punt, C. J. A.
Guchelaar, H-J
BRITISH JOURNAL OF CANCER, 2008, 99 (02) : 275 - 282
[24] UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study
D M Kweekel
H Gelderblom
T Van der Straaten
N F Antonini
C J A Punt
H-J Guchelaar
British Journal of Cancer, 2008, 99 : 275 - 282
[25] The usefulness of UGT1A1 polymorphism testing before starting irinotecan-based chemotherapy.
Harada, Taishi
Saito, Haruhiro
Sugiura, Makiko
Murakami, Shuji
Kondo, Tetsuro
Oshita, Fumihiro
Yamada, Kouzo
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[26] Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai
Xun Cai
Weiguo Cao
Honghua Ding
Tianshu Liu
Xinli Zhou
Mei Wang
Ming Zhong
Ziyi Zhao
Qing Xu
Liwei Wang
Journal of Cancer Research and Clinical Oncology, 2013, 139 : 1579 - 1589
[27] Meta-analysis revisiting the influence of UGT1A1*28 and UGT1A1*6 on irinotecan safety in colorectal cancer patients
Thu Nguyen, Cuc Thi
Minh Thuy, Nguyen Thi
Huong, Phung Thanh
PHARMACOGENOMICS, 2024, 25 (10-11) : 469 - 477
[28] Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai
Cai, Xun
Cao, Weiguo
Ding, Honghua
Liu, Tianshu
Zhou, Xinli
Wang, Mei
Zhong, Ming
Zhao, Ziyi
Xu, Qing
Wang, Liwei
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (09) : 1579 - 1589
[29] A UGT1A1 genotype-directed phase I study of irinotecan (CPT-11) combined with fixed dose of capecitabine in patients with metastatic colorectal cancer (mCRC)
Kim, T.
Sym, S.
Lee, S.
Ryu, M.
Lee, J.
Chang, H.
Kim, H.
Shin, J.
Kang, Y.
Lee, J.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[30] Value of plasma SN-38 levels and DPD activity in irinotecan-based individualized chemotherapy for advanced colorectal cancer with heterozygous type UGT1A1*6 or UGT1A1*28
Tian, Chuan
Ying, Haifeng
Zhuang, Rongyuan
Zhang, Xiaowei
Lu, Hongmin
Wang, Hui
Wang, Shuowen
Li, Qi
Wang, Chungang
Cai, Xun
CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 6217 - 6226

← 1 2 3 4 5 →